Could CAR t cells unlock transplants for 'Impossible to Match' kidney patients?

NCT ID NCT06056102

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a new type of immunotherapy called CAR T cells can safely lower the immune system's reactivity in people waiting for a kidney transplant. Participants have a very high chance of rejecting most donor kidneys (cPRA of 99.5% or higher). The treatment involves giving two types of CAR T cells along with chemotherapy to try to reduce this immune barrier. The main goal is to check safety and find the right dose, with a secondary hope of making more kidneys available for transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CAR T cells (CART-BCMA and huCART19) plus chemotherapy (cyclophosphamide)

What this could lead to

If it works, this could help people with very high immune reactivity receive a kidney transplant they would otherwise be rejected for.

What could go wrong

This is a very early, small Phase 1 trial focused on safety, so it may not work as hoped. CAR T therapy can cause serious side effects like cytokine release syndrome and neurotoxicity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital: Transplantation (Site #: 71107)

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NYU Langone Health (Site #: 71177)

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania Medical Center (Site #: 71111)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••